What Fecal Elastase and Alpha-1 Antitrypsin Measure
Fecal elastase-1 measures pancreatic exocrine function and is used to diagnose exocrine pancreatic insufficiency (EPI), while fecal alpha-1 antitrypsin measures gastrointestinal protein loss and is used to diagnose protein-losing enteropathy.
Fecal Elastase-1
Fecal elastase-1 is a pancreatic enzyme that serves as an indirect marker of pancreatic digestive enzyme production 1, 2. This test has become the preferred noninvasive method for assessing pancreatic function, largely replacing older invasive tests and other indirect methods like stool chymotrypsin assays 2.
What It Measures
- Pancreatic enzyme secretion capacity: Elastase-1 is a serine protease produced by the pancreas that remains stable during intestinal passage, reaching stool concentrations 5-6 times higher than in duodenal juice 2
- Severity of pancreatic insufficiency: The test distinguishes between normal function, moderate insufficiency, and severe EPI 1
Interpretation
- Normal: 200-500 μg/g 2
- Mild to moderate insufficiency: 100-200 μg/g 2
- Severe insufficiency: <100 μg/g 2
- Most reliable for severe EPI: Some suggest <50 μg/g is most reliable for severe disease 1
Key Advantages
- Requires only a single 100 mg stool sample 2
- Not affected by pancreatic enzyme replacement therapy (PERT), unlike other tests 1, 2
- Not affected by diet 2
- Stable in stool for up to one week at room temperature 2
Important Limitations and Pitfalls
Critical caveat: The test performs poorly in mild pancreatic insufficiency with sensitivities <60% 2. For moderate to severe EPI, sensitivity ranges from 73-100% with specificity of 80-100% 2.
Major pitfall: Liquid or watery stools cause false-positive results (falsely low elastase levels due to dilution) 2. This is a common error in clinical practice—always ensure the stool sample is formed before interpreting results.
The test cannot reliably distinguish pancreatic from non-pancreatic causes of malabsorption 2.
Fecal Alpha-1 Antitrypsin
Fecal alpha-1 antitrypsin serves as an endogenous marker of gastrointestinal protein loss 3, 4. It measures plasma protein leakage into the intestinal tract.
What It Measures
- Protein-losing enteropathy: Alpha-1 antitrypsin is a plasma protein that, when elevated in stool, indicates abnormal loss of plasma proteins through the gastrointestinal tract 3, 4
- Intestinal permeability to plasma proteins: The test correlates well with radiolabeled protein studies (51Cr-plasma protein clearance, r = 0.96) 3
Interpretation
Results are typically expressed as fecal clearance (mL/day) rather than simple concentration 3, 4:
- Normal clearance: Up to approximately 60 mL/day (though this increases with diarrhea) 4
- Clinically significant protein loss: Clearance >180 mL/day typically correlates with serum albumin <3.0 g/dL 4
- Sensitivity and specificity: 93.3% and 90% respectively when compared to 51Cr studies 3
Important Limitations and Pitfalls
Critical caveat: Diarrhea itself can increase alpha-1 antitrypsin clearance, even without true protein-losing enteropathy 4. Normal values must account for stool consistency to avoid overdiagnosis.
Major pitfall: Alpha-1 antitrypsin is destroyed in gastric juice with pH <3 3. Therefore, this test is not useful for detecting protein loss from the stomach—it only detects intestinal protein loss.
Measurement method matters: Fecal alpha-1 antitrypsin concentration alone is not reliable; clearance calculation is necessary for accurate diagnosis 4. Radial immunodiffusion has better sensitivity than nephelometry because protease-antiprotease complexes can decrease apparent concentrations with some methods 5.
Clinical Context
The test is particularly useful in:
- Unexplained hypoalbuminemia with chronic diarrhea 4
- Suspected inflammatory bowel disease (some patients with microscopic/collagenous colitis show elevated clearance) 4
- Differentiating protein-losing enteropathy from other causes of hypoalbuminemia
Unlike fecal elastase, fecal alpha-1 antitrypsin is not affected by Roux-en-Y gastric bypass 6, making it reliable in post-bariatric surgery patients.